Search

Vir Biotechnology Inc

Fermé

SecteurSoins de santé

10.65 7.47

Résumé

Variation du prix de l'action

24h

Actuel

Min

9.92

Max

11.25

Chiffres clés

By Trading Economics

Revenu

80M

-46M

Ventes

239M

239M

BPA

0.47

Marge bénéficiaire

-19.09

Employés

367

EBITDA

201M

78M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+114.83% upside

Dividendes

By Acuity

Prochains Résultats

4 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

176M

1.7B

Ouverture précédente

3.18

Clôture précédente

10.65

Sentiment de l'Actualité

By Acuity

50%

50%

167 / 340 Classement par Healthcare

Vir Biotechnology Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 août 2026, 20:09 UTC

Social Media

Vir Biotechnology is gaining as social media discussions highlight its $1 billion cash position and potential catalysts, despite earlier session pullbacks.

24 août 2026, 21:01 UTC

Vir Biotechnology Inc. shares are trading higher in after-market hours, continuing a recent upward trend amid a rebound in the bond market and lower Treasury yields.

21 août 2026, 20:02 UTC

Correlated Moves

Vir Biotechnology Inc. shows upward momentum, reflecting significant gains since Thursday's close, amid positive trends in the healthcare sector and broader biotechnology market.

20 août 2026, 20:02 UTC

Correlated Moves

Vir Biotechnology Inc. shares are trading lower amid a significant decline in the biotechnology sector, influenced by broader market trends and ETF performance.

19 août 2026, 23:06 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher in after-market trading, continuing a positive trend and maintaining a position above their 20-day moving average.

18 août 2026, 19:56 UTC

Vir Biotechnology Inc shares are higher today, reflecting positive market sentiment, despite a pullback from earlier session gains. The stock remains above its 20-day moving average.

17 août 2026, 21:02 UTC

Vir Biotechnology Inc is trading higher in after-market hours, maintaining positive momentum after eight consecutive sessions of gains and exceeding its 20-day moving average.

11 août 2026, 19:36 UTC

Vir Biotechnology Inc. shares are trading roughly flat amid geopolitical tensions and anticipation of U.S. inflation reports that could influence Federal Reserve policy.

10 août 2026, 23:56 UTC

Vir Biotechnology Inc. shares advanced in after-market trading, reflecting a modest increase from Monday's close, though still below the 20-day moving average.

7 août 2026, 19:36 UTC

Correlated Moves

Vir Biotechnology shares are higher, supported by broader market gains and a notable increase in the ARK Genomic Revolution ETF.

6 août 2026, 23:21 UTC

Vir Biotechnology Inc shares are higher in after-market trading, showing positive momentum following Thursday's close. No specific news was identified to explain the movement.

5 août 2026, 23:41 UTC

News
Social Media

Vir Biotechnology reported second-quarter revenue of $238.9 million, exceeding estimates, contributing to significant gains in after-market trading.

3 août 2026, 19:46 UTC

Vir Biotechnology Inc's shares are higher today, reflecting broader market trends amid falling oil prices. The stock remains below its 20-day moving average.

30 juil. 2026, 19:58 UTC

Vir Biotechnology Inc shares are higher today amid a broader recovery in tech stocks, despite breaking a recent trend of higher daily closes.

29 juil. 2026, 19:27 UTC

Shares of Vir Biotechnology Inc. are trading lower today, having declined after an initial uptick and hitting a session low in late morning.

28 juil. 2026, 15:46 UTC

Correlated Moves

Shares lower today, pressured by declines in biotech sector.

27 juil. 2026, 20:07 UTC

Vir Biotechnology's shares are higher today, continuing gains since Friday. The broader market is influenced by declining oil prices and lower Treasury yields.

25 juil. 2026, 00:01 UTC

Vir Biotechnology Inc shares are higher in after-market trading, recovering from earlier lows. The stock is near the lower end of its one-month trading range.

24 juil. 2026, 23:31 UTC

Vir Biotechnology Inc shares are higher in after-market trading, reflecting notable gains since Friday's close, despite no specific news driving the price action.

21 juil. 2026, 17:16 UTC

Correlated Moves

Vir Biotechnology Inc's shares are higher today, supported by a positive trend in the broader biotech sector. Earlier, shares pulled back but have since recovered.

20 juil. 2026, 21:02 UTC

Vir Biotechnology Inc shares fell during after-market hours amid broader market declines following a reported drop in the Leading Economic Index for June.

Comparaison

Variation de prix

Vir Biotechnology Inc prévision

Objectif de Prix

By TipRanks

114.83% hausse

Prévisions sur 12 Mois

Moyen 21.29 USD  114.83%

Haut 30 USD

Bas 15 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

8

Achat

0

Maintien

0

Vente

Sentiment

By Acuity

167 / 340Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vir Biotechnology Inc

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
help-icon Live chat